Abstract:

Objective     To investigate the therapeutic effects of rosiglitazone on the level of serum glucagon-like peptide-1(GLP-1). Methods     74 type 2 diabetes patients, who were under insulin and metformin therapy, were divided into two groups: a) study group,  in which 38 patients took use of insulin combined with rosiglitazone (4mg/day, orally) for 6 months; b) control group, including 36 patients. Limosis serum glucagon-like peptide-1(GLP-1),  glycated hemoglobin(HbA1c), and limosis insulin(FINS) were measured by  enzyme-linked-immunosorbent assay (ELISA), column chromatography and  chemiluminescence, respectively. The oxidase method was applied to examine the fasting blood glucose(FPG)、 2h postprandial blood glucose(2hPG)、 triglyceride(TG) and total cholesterol(TC).  Changes of blood glucose, insulin, HbA1c, blood lipid and GLP-1 were observed before and after treatment. Results      There were no differences in age、years of diabetes mellitus、body mass index and gender between the two groups(P＞0.05). In the first group, FPG, 2hFG, HbA1c, FINS,TC, and TG significantly decreased after a 6-month treatment (P＜0.05), while the group showed an increased GLP-1 secretion compared with the control(P＜0.05). Conclusions      Rosiglitazone can effectively control blood glucose and HbA1c, lower insulin resistance, and increase serum levels of GLP-1 in patients with type 2 diabetes.

Key words:  Diabetes mellitus， type 2； Insulin resistance； Rosiglitazone； Glucagon-like peptide-1